课题基金 / 基金详情

EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL

EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON SICKLE CELL
低分子肝素对镰状细胞的影响
批准号：
6308599
负责人：
LORI A STYLES
金额：
$1.75万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6308599
关键词：
anticoagulants blood disorder chemotherapy child (0-11) clinical research drug screening /evaluation heparin human subject human therapy evaluation sickle cell anemia

项目摘要

项目成果

LORI A STYLES的其他基金

相关文献

中文摘要
翻译
镰状细胞病是一种常见的B型血红蛋白病，可导致相当大的发病率和死亡率。SCD的特点是促凝状态，这可能是镰状红细胞(SRBC)与内皮细胞相互作用的结果。SCD的止血异常包括通过组织因子(TF)的产生增加促凝血因子的增加以及蛋白C途径中抗凝血因子的减少。这种失衡的结果是凝血酶形成明显增加。低分子肝素(LMWH)是一种简单、有效、安全的抗凝治疗方法，可用于治疗SCD症状，但尚未被用于治疗镰状细胞病(SCD)。
英文摘要
Sickle cell disease is a common B hemoglobinopathy which results in substantial morbidity and mortality. SCD is characterized by a procoagulant state which likely results from the interaction of sickled red blood cells (SRBC) with the endothelium. Hemostatic abnormalities in SCD include an increase in procoagulant factors via an increase in tissue factor (TF) production as well as a decrease in anticoagulant factors in the protein C pathway. The result of this imbalance is a well characterized increase in thrombin formation. Low molecular weight heparin (LMWH) is a simple, effective and safe means of anticoagulant therapy which could be used to treat SCD manifestations but has never been evaluated in sickle cell disease (SCD).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Arginine as Prophylactic Therapy in Sickle Cell Disease
Arginine as Prophylactic Therapy in Sickle Cell Disease
Arginine as Prophylactic Therapy in Sickle Cell Disease
Arginine as Prophylactic Therapy in Sickle Cell Disease